Page 4 - கனடியன் நிறுவனம் ஆஃப் ஆரோக்கியம் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/R E P E A T -- Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression/

/R E P E A T -- Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression/
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Roger mcintyreRogers mcintyreJosh rosenblatJoshua rosenblatBraxia scientific corpNational institute of healthToronto university health networkResearch clinicExcellence incBraxia health canadian rapid treatment centerCanadian institute of health researchHealth canadaCanadian rapid treatment centerCanadian instituteHealth researchUniversity health network

Braxia Scientific Corp receives Canadian government funding for first-of-its-kind study on ketamine treatment for bipolar depression

Braxia Scientific Corp receives Canadian government funding for first-of-its-kind study on ketamine treatment for bipolar depression
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Roger mcintyreJoshua rosenblatBraxia scientific corpToronto university health networkCanadian institute of health researchBraxia canadian rapid treatment centerCanadian rapid treatment centerCanadian instituteHealth researchUniversity health networkChief medicalScience officer joshua rosenblatHealth canada approvedCanadian governmentBraxia scientificரோஜர் முசந்த்ிரே

AFib Rhythm Control Versus Rate Control Strategy in Heart Failure Showed No Differences

AFib Rhythm Control Versus Rate Control Strategy in Heart Failure Showed No Differences RAFT-AF study showed type of heart failure may influence treatment strategies RAFT-AF study showed the type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. Getty Images May 19, 2021 Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm using catheter ablation and those focused on controlling the heart rate using drugs and/or a pacemaker, showed no significant differences in terms of death from any cause or progression of heart failure This was the result of RAFT-AF study presented at the American College of Cardiology (ACC) 2021 Scientific Session.

City ofUnited kingdomAnthony sl tangAmerican college of cardiologyCanadian institute of health researchAmerican collegeWestern universityCanadian instituteநகரம் ஆஃப்ஒன்றுபட்டது கிஂக்டம்அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்கனடியன் நிறுவனம் ஆஃப் ஆரோக்கியம் ஆராய்ச்சிஅமெரிக்கன் கல்லூரிமேற்கு பல்கலைக்கழகம்கனடியன் நிறுவனம்

Type of heart failure may influence treatment strategies in patients with AFib

Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on controlling the heart rhythm (using catheter ablation) and those focused on controlling the heart rate (using drugs and/or a pacemaker) showed no significant differences in terms of death from any cause or progression of heart failure, according to a study presented at the American College of Cardiology s 70th Annual Scientific Session.

City ofUnited kingdomAnthony sl tangAmerican college of cardiologyCanadian institute of health researchAmerican collegeAnnual scientificWestern universityCanadian instituteHeart failureHigh burden atrial fibrillationMedicine healthClinical trialsநகரம் ஆஃப்ஒன்றுபட்டது கிஂக்டம்அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்

Researchers Find Marker that Could Predict Response to Cancer – The News Chronicle

Micorscope is used by researcher who use her hands holding and adjusting while science research in laboratory Researchers at University of Alberta have uncovered a link between the expression of the protein galectin-9 (gal-9) and whether a cancer patient will benefit from immunotherapy. The discovery could help inform physicians about which patients will likely respond to immunotherapy, and lead to better treatment options. Shokrollah Elahi, a member of the Cancer Research Institute of Northern Alberta (CRINA), collaborated with oncology professor John Walker on Phase 2 clinical trial that examined 40 patients with virus-associated solid tumours (VASTs) who were put on immunotherapy. They found there was a direct link between patients with high levels of gal-9 and those who had a poor prognosis and did not respond to immunotherapy. Further, patients with lower levels of gal-9 responded better to treatment.

Shokrollah elahiAlberta cancer foundationCancer research institute of northern albertaChildren health research instituteCanadian institute of health researchResearchers at university of albertaLi ka shing institute of virologyCancer research instituteNorthern albertaJohn walkerHealth research instituteCanadian instituteHealth researchஆல்பர்ட்டா புற்றுநோய் அடித்தளம்புற்றுநோய் ஆராய்ச்சி நிறுவனம் ஆஃப் வடக்கு ஆல்பர்ட்டாகுழந்தைகள் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம்